Paraneoplastic disorders

Published on 20/03/2015 by admin

Filed under Pathology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1490 times

47

Paraneoplastic disorders

Patients with a primary neoplasm remote from the CNS may develop neurologic symptoms and signs as a consequence of:

image Spread of the neoplasm to the nervous system (see Chapter 46).

image Systemic metabolic and hemodynamic disturbances (Table 47.1).

Table 47.1

Cancer-related systemic disorders producing CNS symptomatology

Metabolic/endocrine disorders Potential etiology
Hepatic failure Liver metastases
Hypoglycemia Consumption of glucose by disseminated sarcoma
Hyponatremia Syndrome of inappropriate ADH secretion
Hypercalcemia Bone metastases/inappropriate parathyroid hormone production
Cushing syndrome Inappropriate (ectopic) ACTH production
Wernicke–Korsakoff syndrome Thiamine deficiency secondary to emesis
Vascular disorders Potential etiology
Encephalopathy/infarction–hyperviscosity Waldenstrom’s macroglobulinemia
Infarction–hypercoagulability state Mucin-secreting adenocarcinomas
Infarction Polycythemia rubra vera
Embolic infarction Marantic endocarditis
Hemorrhage Reduced coagulation factors in hepatic failure
Thrombocytopenia in bone marrow failure

image Infections secondary to immunosuppression produced by lymphoreticular neoplasms (Table 47.2).

Table 47.2

CNS infections particularly associated with lymphomas, leukemias, and myeloma

Organism Particular clinical association
Varicella zoster virus encephalitis Hodgkin’s disease
Herpes simplex virus encephalitis Hodgkin’s disease
Cytomegalovirus encephalitis Acute lymphoblastic leukemia
Progressive multifocal leukoencephalopathy (JC papovavirus) Various
Listeria infection Post-splenectomy
Streptococcal meningitis Post-splenectomy
Toxoplasmosis Lymphoma
Cryptococcal meningoencephalitis Various
CNS aspergillosis Various

image Side-effects of cancer therapy (Table 47.3).

Table 47.3

CNS side-effects of cancer treatment

Radiotherapy

Encephalopathy

Delayed myelopathy

Hypothalamic/pituitary disturbances

Oncogenesis – mainly meningioma, sarcoma, glioma

Chemotherapy

Encephalopathy and/or myelopathy (particularly after BCNU, L-asparaginase, intrathecal methotrexate)

Cerebellar disorder (cytosine arabinoside)

image Production of antibodies that simultaneously target onconeural antigens on neurons and neoplastic cells (Table 47.4), which is the subject of this chapter.

Paraneoplastic syndromes are rare, affecting less than 1% of patients with cancer but they may be extremely debilitating and sometimes fatal. They may involve the CNS or peripheral nervous system, or produce a myopathy. Syndromes generally evolve over a period of a few weeks or months. The principal CNS paraneoplastic syndromes are:

Rare CNS paraneoplastic syndromes include chorea, dystonia, motor neuron disease, and stiff person syndrome.

Two or more nervous system paraneoplastic syndromes may coexist, being produced by the same antibody (e.g. encephalomyelitis and sensory neuronopathy produced by anti-Hu antibodies). The causal tumor may not be evident at the time of neurologic presentation. The paraneoplastic disorder frequently dominates the clinical picture, possibly because neoplastic growth is inhibited by the immune response.

Pathogenic theories of paraneoplastic nervous system disorders presume that onconeural antigens are expressed on cells in immunologically privileged sites, such that they are immunogenic when expressed in neoplastic cells, and that autoimmunity subsequently develops in a subset of patients with onconeural antibodies.

Evidence for an autoimmune process is provided by the demonstration of:

Although the demonstration of antibodies to onconeural antigens has provided clinicians with a useful diagnostic test, it is clear that not all patients with paraneoplastic syndromes have detectable antibodies, and paraneoplastic syndromes may be caused by antibodies other than those that have been characterized to date. Antibodies directly mediate the pathology of myasthenia gravis and Lambert–Eaton myasthenic syndrome, but the pathogenesis of most antibody-associated paraneoplastic syndromes involves a cytotoxic T cell response.

PARANEOPLASTIC ENCEPHALOMYELITIS

MACROSCOPIC AND MICROSCOPIC APPEARANCES

The histologic features of PEM are similar to those of viral encephalitis and myelitis. Neuronal loss, astrocytosis, and an increase in activated microglia are accompanied by an inflammatory infiltrate that consists mainly of lymphocytes and plasma cells and is concentrated in perivascular spaces (Fig. 47.1). The extent of the inflammation is variable and correlates poorly with neuronal loss. Inflammation affects gray matter, but secondary degeneration of white matter tracts can result. A leptomeningitis is nearly always present. No macroscopic abnormalities may be discerned.

Regions of the cerebrum, brain stem, cerebellum, spinal cord, and optic nerve may be affected alone or in combination.

Some cases of PEM are combined with a sensory neuronopathy characterized by ganglionitis, loss of ganglion cells, and secondary degeneration of dorsal column fibers (Fig. 47.2).

PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD)

MACROSCOPIC AND MICROSCOPIC APPEARANCES

Mild cerebellar atrophy is occasionally observed, but there is generally no macroscopic abnormality in PCD. Histologically, a severe loss of Purkinje cells is evident throughout most of the cerebellar cortex, and is accompanied by variable loss of granule cells, activated microglia, and Bergmann gliosis (Fig. 47.3). An infiltrate of mononuclear leukocytes may be seen in the cortex, and there may be perivascular aggregates of lymphocytes and a leptomeningitis. However, inflammation may be sparse or absent, despite a severe loss of Purkinje cells. In a minority of cases of PCD, there is patchy loss of neurons accompanied by inflammation in other regions of the brain, indicating some overlap with PEM.

REFERENCES

Carpentier, A.F., Delattre, J.Y. The Lambert–Eaton myasthenic syndrome. Clin Rev Allergy Immunol.. 2001;20:155–158.

Dalmau, J., Graus, F., Rosenblum, M.K., et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore).. 1992;71:59–72.

Dalmau, J., Gultekin, H.S., Posner, J.B., et al. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol.. 1999;9:275–284.

Darnell, R.B., Posner, J.B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol.. 2006;33:270–298.

Darnell, R.B., Posner, J.B. Autoimmune encephalopathy: the spectrum widens. Ann Neurol.. 2009;66:1–2.

Graus, F., Keime-Guibert, F., Reñe, R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain.. 2001;124:1138–1148.

Henson R.A., Urich H., eds. Cancer and the nervous system. Oxford: Blackwell Scientific, 1982.

McKeon, A., Pittock, S.J. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol.. 2011;122:381–400.

Rosenfeld, M.R., Dalmau, J. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin Neurol.. 2010;30:320–331.